| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | NEUTRAL | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.42▲ | 1.41▲ | 1.39▲ | 1.39▲ | 1.82▼ |
| MA10 | 1.41▲ | 1.41▲ | 1.37▲ | 1.46▼ | 0.97▲ |
| MA20 | 1.39▲ | 1.36▲ | 1.34▲ | 1.65▼ | 0.60▲ |
| MA50 | 1.35▲ | 1.37▲ | 1.43▼ | 0.72▲ | 0.50▲ |
| MA100 | 1.35▲ | 1.52▼ | 1.58▼ | 0.49▲ | N/A |
| MA200 | 1.50▼ | 1.50▼ | 1.01▲ | 0.44▲ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.001▲ | 0.010▲ | 0.019▲ | -0.083▼ | 0.174▲ |
| RSI | 55.250▲ | 53.875▲ | 52.896▲ | 55.389▲ | 60.810▲ |
| STOCH | 69.351 | 57.240 | 65.150 | 17.968▼ | 65.359 |
| WILL %R | -41.176 | -35.897 | -24.138▲ | -81.600▼ | -42.433 |
| CCI | 34.568 | 48.030 | 82.337 | -52.924 | 64.290 |
|
Friday, February 13, 2026 07:44 AM
New independent director Phillip Balatsos brings commercial and capital markets expertise to drive development ...
|
|
Thursday, February 12, 2026 03:05 AM
New sublingual delivery system designed to provide more rapid relief from nausea caused by cancer medicines Ondansetron, currently sold under the brand name Zofran ®, was the 53rd most commonly ...
|
|
Wednesday, February 11, 2026 09:22 PM
New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 13/02/26 | 1.29 | 1.50 | 1.2857 | 1.43 | 475,618 |
| 12/02/26 | 1.33 | 1.36 | 1.20 | 1.31 | 427,608 |
| 11/02/26 | 1.29 | 1.39 | 1.21 | 1.35 | 9,744,157 |
| 10/02/26 | 1.46 | 1.4806 | 1.37 | 1.41 | 347,384 |
| 09/02/26 | 1.43 | 1.4828 | 1.3612 | 1.44 | 144,856 |
| 06/02/26 | 1.35 | 1.49 | 1.26 | 1.46 | 207,063 |
| 05/02/26 | 1.54 | 1.54 | 1.26 | 1.32 | 403,877 |
| 04/02/26 | 1.61 | 1.64 | 1.4869 | 1.55 | 214,573 |
| 03/02/26 | 1.69 | 1.799 | 1.53 | 1.63 | 405,683 |
| 02/02/26 | 1.99 | 2.01 | 1.44 | 1.70 | 538,636 |
|
|
||||
|
|
||||
|
|